As of 2025-07-01, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (42.83) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.60 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -7234.5%.
The range of the Relative Valuation is (42.43) - (40.83) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 17.9x | 17.4x |
| Forward P/E multiples | 18.6x - 22.0x | 20.1x |
| Fair Price | (42.43) - (40.83) | (42.83) |
| Upside | -7168.0% - -6902.0% | -7234.5% |
| Date | P/E |
| 2025-06-26 | -0.30 |
| 2025-06-25 | -0.24 |
| 2025-06-24 | -0.26 |
| 2025-06-23 | -0.27 |
| 2025-06-20 | -0.30 |
| 2025-06-18 | -0.31 |
| 2025-06-17 | -0.31 |
| 2025-06-16 | -0.31 |
| 2025-06-13 | -0.31 |
| 2025-06-12 | -0.31 |
| 2025-06-11 | -0.34 |
| 2025-06-10 | -0.35 |
| 2025-06-09 | -0.36 |
| 2025-06-06 | -0.37 |
| 2025-06-05 | -0.36 |
| 2025-06-04 | -0.32 |
| 2025-06-03 | -0.31 |
| 2025-06-02 | -0.31 |
| 2025-05-30 | -0.33 |
| 2025-05-29 | -0.32 |
| 2025-05-28 | -0.32 |
| 2025-05-27 | -0.29 |
| 2025-05-23 | -0.28 |
| 2025-05-22 | -0.27 |
| 2025-05-21 | -0.23 |
| 2025-05-20 | -0.26 |
| 2025-05-19 | -0.22 |
| 2025-05-16 | -0.20 |
| 2025-05-15 | -0.18 |
| 2025-05-14 | -0.19 |
| 2025-05-13 | -0.17 |
| 2025-05-12 | -0.17 |
| 2025-05-09 | -0.18 |
| 2025-05-08 | -0.16 |
| 2025-05-07 | -0.15 |
| 2025-05-06 | -0.16 |
| 2025-05-05 | -0.17 |
| 2025-05-02 | -0.16 |
| 2025-05-01 | -0.15 |
| 2025-04-30 | -0.14 |
| 2025-04-29 | -0.12 |
| 2025-04-28 | -0.16 |
| 2025-04-25 | -0.28 |
| 2025-04-24 | -0.32 |
| 2025-04-23 | -0.30 |
| 2025-04-22 | -0.17 |
| 2025-04-21 | -0.14 |
| 2025-04-17 | -0.13 |
| 2025-04-16 | -0.13 |
| 2025-04-15 | -0.14 |